- Report
- May 2024
- 133 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- May 2024
- 130 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- May 2024
- 132 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- May 2024
- 139 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- May 2024
- 130 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- May 2024
- 137 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- May 2024
- 139 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1820EUR$2,000USD£1,546GBP
- Report
- April 2025
- 200 Pages
Global
From €7236EUR$7,950USD£6,146GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- May 2024
- 160 Pages
Global
From €4523EUR$4,969USD£3,841GBP
- Report
- October 2024
- 200 Pages
Global
From €3413EUR$3,750USD£2,899GBP
- Report
- March 2025
- 217 Pages
Global
From €2275EUR$2,500USD£1,933GBP
- Report
- March 2025
- 186 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- March 2025
- 180 Pages
Global
From €4096EUR$4,500USD£3,479GBP
- Report
- July 2024
Global
From €4414EUR$4,850USD£3,749GBP
- Report
- March 2025
- 131 Pages
Global
From €3973EUR$4,365USD£3,374GBP
€4414EUR$4,850USD£3,749GBP
- Report
- March 2025
- 133 Pages
Global
From €3973EUR$4,365USD£3,374GBP
€4414EUR$4,850USD£3,749GBP
- Report
- February 2025
- 140 Pages
Global
From €3973EUR$4,365USD£3,374GBP
€4414EUR$4,850USD£3,749GBP

Selective Serotonin Reuptake Inhibitors (SSRIs) are a class of drugs used to treat mental disorders such as depression, anxiety, and obsessive-compulsive disorder. SSRIs work by increasing the amount of serotonin, a neurotransmitter, in the brain. This helps to improve mood and reduce symptoms of mental illness. SSRIs are generally considered to be safer and more effective than other types of antidepressants, and they are often prescribed as a first-line treatment for mental disorders.
The SSRI market is highly competitive, with many pharmaceutical companies offering different brands of SSRIs. Some of the major players in the market include Pfizer, GlaxoSmithKline, Eli Lilly, and AstraZeneca. These companies have developed a wide range of SSRIs, including Prozac, Zoloft, Paxil, and Lexapro. Other companies, such as Mylan and Teva, also offer generic versions of SSRIs. Show Less Read more